Comparative Safety and Efficacy of Intravenous Tranexamic Acid Versus IV Carbetocin in Reducing Blood Loss During Abdominal Myomectomy: a Randomized Controlled Trial
Overview
- Phase
- Phase 4
- Intervention
- intravenous carbetocin
- Conditions
- Myomectomy
- Sponsor
- Cairo University
- Enrollment
- 153
- Primary Endpoint
- intraoperative blood loss
- Last Updated
- 6 years ago
Overview
Brief Summary
the aim of the present study is to compare safety and efficacy of intravenous tranexamic acid versus IV carbetocin in reducing blood loss during abdominal myomectomy: a randomized controlled trial
Investigators
Ahmed Samy aly ashour
assistant professor obstetrics and gynecology
Cairo University
Eligibility Criteria
Inclusion Criteria
- •women with symptomatic fibroids candidate for abdominal myomectomy with staging of myoma from (3 to 6) according to FIGO staging
Exclusion Criteria
- •women with Myoma FIGO staging (1,2,7 and 8) candidate for laparoscopic or hysteroscopic myomectomy, women with allergy or contraindications to carbetocin or tranexamic acid
Arms & Interventions
intravenous carbetocin
The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision
Intervention: intravenous carbetocin
placebo
the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision
Intervention: placebo
intravenous tranexamic acid
The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision
Intervention: intravenous tranexamic acid
Outcomes
Primary Outcomes
intraoperative blood loss
Time Frame: one hour
the intraoperative blood loss in ml will be estimated during the procedure
Secondary Outcomes
- need for blood transfusion(24 hours)